テラドックヘルスの適時開示・その他

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported) September 20, 2023

___________________________________

Teladoc Health, Inc.

(Exact name of registrant as specified in its charter)

___________________________________


Delaware (State or other jurisdiction of incorporation or organization)	001-37477 (Commission File Number)	04-3705970 (I.R.S. Employer Identification Number)
2 Manhattanville Road Suite 203 Purchase, NY 10577
(Address of principal executive offices and zip code)
(203) 635-2002
(Registrant's telephone number, including area code)

___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:
Title of each class	Trading Symbol	Name of each exchange on which registered
Common stock, par value $0.001 per share	TDOC	The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective September 20, 2023, the Board of Directors (the “Board”) of Teladoc Health, Inc. (the “Company”) increased the number of directors on the Board to ten and appointed J. Eric Evans as a director of the Company. Mr. Evans was additionally appointed to the compensation committee of the Board. The Board has determined that Mr. Evans is an independent director within the meaning of the New York Stock Exchange listing standards.

There are no arrangements or understandings between Mr. Evans and any other person pursuant to which he was selected as a director. There are no transactions involving the Company and Mr. Evans that the Company would be required to report pursuant to Item 404(a) of Regulation S-K.

Mr. Evans will have the same director indemnification arrangement as do the Company’s other directors appointed since October 2020, the form of agreement for which was filed with the Securities and Exchange Commission (the “SEC”) on March 1, 2021 as Exhibit 10.2 to the Company’s Annual Report on Form 10-K. Mr. Evans will be eligible to participate in the compensation arrangements and programs that are established for the Company’s non-employee directors, as in effect from time to time, which are described in the Company’s Proxy Statement on Schedule 14A filed with the SEC on April 11, 2023.

Item 7.01. Regulation FD.

On September 20, 2023, the Company issued a press release regarding the matter discussed in Item 5.02 of this Current Report. A copy of the press release is furnished herewith as Exhibit 99.1.

The information furnished under this Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.						Description
99.1						Teladoc Health, Inc. press release, dated September 20, 2023.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 20, 2023


Teladoc Health, Inc.

By:			/s/ Adam C. Vandervoort
Name:			Adam C. Vandervoort
Title:			Chief Legal Officer and Secretary

EX-99.1 2 exhibit991.htm EX-99.1 Document

Exhibit 99.1

Teladoc Health Appoints Leading Healthcare and Hospitals Executive

Eric Evans to Board of Directors

Purchase, NY, September 20, 2023 – Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, today appointed Eric Evans to the company’s board of directors. Mr. Evans, currently chief executive officer and director of Brentwood, TN-based Surgery Partners, Inc. (NASDAQ:SGRY), is a recognized healthcare and hospital executive with significant experience leading complex organizations operating at the intersection of care and technology. Mr. Evans joins the board following the retirement of Senator William Frist, M.D. earlier this year, and will serve on the board’s compensation committee.

David B. Snow, Jr., non-executive Chairman of the company’s board, said: “We are extremely pleased to welcome Eric to Teladoc Health’s board of directors. Eric brings the perfect combination of talent, experience, and mindset to today’s Teladoc Health as we work closely with our clients to enhance our services and offerings, invest in a robust innovation pipeline, and deliver solutions that are transforming healthcare globally.”

Surgery Partners is a leading operator of surgical facilities and ancillary services with more than 180 locations nationwide. During his tenure, beginning in early 2019, Mr. Evans has scaled the business, adding a net 29 new facilities to its portfolio, growing revenue over 50% and earnings over 70%, which has driven approximately $3.5 billion of market capitalization growth. Prior to joining Surgery Partners, Mr. Evans was President of Hospital Operations at Tenet Healthcare, with responsibility for 68 acute care hospitals, 161 hospital-affiliated facilities, and more than 2,200 employed providers. He has a BS in industrial management from Purdue University and an MBA from Harvard Business School.

“It’s a privilege to join the Teladoc Health board of directors and to share my nearly two decades of experience in the integrated healthcare arena,” said Mr. Evans. “I’ve admired Teladoc Health for years and witnessed firsthand the ways in which the company has reinvented healthcare delivery for millions of employers, health plans, governments, and individuals. I look forward to collaborating with my fellow board members and working closely with the management team led by Jason Gorevic to write the next chapter in the company’s evolution.”

Teladoc Health reported second quarter financial results, in July 2023, with strong financial and operating results across all key metrics, including a 10% increase in revenues to $652.4 million and adjusted EBITDA of $72.2 million that exceeded expectations. Also, in July 2023, Teladoc Health expanded its collaboration in artificial intelligence with Microsoft to address the healthcare workforce crisis.

About Teladoc Health

Teladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in whole-person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey. Teladoc Health leverages more than two decades of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com.

Media:
Chris Stenrud
860-491-8821
pr@teladochealth.com